Zhang Jeff F, Piryani Ravi, Swayampakula Anil K, Farooq Osman
Jacobs School of Medicine and Biomedical Sciences University at Buffalo Buffalo New York USA.
Division of Critical Care Medicine Department of Pediatrics University at Buffalo Buffalo New York USA.
Clin Case Rep. 2022 Mar 15;10(3):e05586. doi: 10.1002/ccr3.5586. eCollection 2022 Mar.
Levetiracetam is a second-generation antiepileptic medication used to treat a wide range of partial and generalized seizure disorders. While Levetiracetam is generally well-tolerated, mild mood-related side effects (e.g., anxiety, agitation, and depression) have been observed in a minority of patients in the days following initiation of therapy or changes in dosing. The development of acute aggression requiring termination of Levetiracetam therapy has been rarely reported in the medical literature but poses a limiting effect on treatment options for refractory epilepsy in pediatric patients. In this report, we present a teenage male patient with a history of seizure disorder who developed sudden, severe behavioral abnormalities and aggression following increases in his Levetiracetam dosing. His symptoms resolved rapidly after return of his medication dosing to baseline, with no further sequelae noted. Our observations suggest that Levetiracetam remains a safe and effective first-line antiepileptic whose adverse behavioral side effect profile can be properly managed with close patient monitoring and dose titration.
左乙拉西坦是一种第二代抗癫痫药物,用于治疗多种局灶性和全身性癫痫发作障碍。虽然左乙拉西坦通常耐受性良好,但在少数患者开始治疗或调整剂量后的几天内,观察到了与情绪相关的轻微副作用(如焦虑、激动和抑郁)。医学文献中很少报道因急性攻击行为而需要终止左乙拉西坦治疗的情况,但这对小儿难治性癫痫的治疗选择产生了限制作用。在本报告中,我们介绍了一名有癫痫病史的青少年男性患者,在增加左乙拉西坦剂量后出现了突然、严重的行为异常和攻击行为。在药物剂量恢复到基线水平后,他的症状迅速缓解,未发现进一步的后遗症。我们的观察结果表明,左乙拉西坦仍然是一种安全有效的一线抗癫痫药物,通过密切的患者监测和剂量滴定,可以妥善管理其不良行为副作用。